BioNovelus Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
-
2.40
-
Cost of Goods Sold (COGS) incl. D&A
-
-
35.00
47.80
35.60
Gross Income
-
-
35.00
45.40
35.60
SG&A Expense
35.90
195.90
49.90
629.70
1,024.00
EBIT
35.90
195.90
85.00
-
1,059.60
Non Operating Income/Expense
-
-
-
-
583.90
Interest Expense
-
-
37.70
37.60
36.00
Pretax Income
35.90
195.90
122.70
712.70
1,679.40
Consolidated Net Income
35.90
195.90
122.70
712.70
1,679.40
Net Income
35.90
195.90
122.70
712.70
1,679.40
Net Income After Extraordinaries
35.90
195.90
122.70
712.70
1,679.40
Net Income Available to Common
35.90
195.90
122.70
712.70
1,679.40
EPS (Basic)
1.83
1.69
0.00
0.01
0.01
Basic Shares Outstanding
19.60
115.90
83,268.00
112,139.10
112,139.10
EPS (Diluted)
1.83
1.69
0.00
0.01
0.01
Diluted Shares Outstanding
19.60
115.90
83,268.00
112,139.10
112,139.10
EBITDA
35.90
-
50.00
628.10
1,024.00
Other Operating Expense
-
-
0.10
-
-
About BioNovelus
View Profile
